Label Free Detection Market

Global Label Free Detection Market Size (2023 to 2028)

As per our research report, the global label-free detection market is estimated to grow at a CAGR of 11.99% during the forecast period. The market size is predicted to value USD 3.55 billion by 2028 and USD 2.01 billion in 2023.

Global Label Free Detection Market Share Insights:

• Based on technology, the SPR segment was the largest segment in the global market in 2022.
• Based on the product, the biosensor chips segment dominated the market in 2022.
• Based on application, the binding kinetics segment accounted for the major share of the global market in 2022.
• Based on region, North America was the biggest regional segment in the worldwide market in 2022.

MARKET DRIVERS:

The growing demand for label-free detection techniques in drug discovery and development is one of the major factors propelling the market growth. The adoption of label-free detection techniques in the pharmaceutical industry is growing rapidly, especially in drug discovery and development to study biomolecular interactions, screen drug candidates, and understand their mechanisms of action. This trend is likely to continue in the coming years and contribute to the market growth. Technological advancements further contribute to the growth of the label-free detection market. The label-free detection techniques have experienced several technological developments in recent years and the market participants have brought several upgrades using technological advancements in techniques such as surface plasmon resonance (SPR), biolayer interferometry (BLI), and quartz crystal microbalance (QCM). These technological advancements further resulted in the improved sensitivity, throughput and data quality of label-free detection techniques.

The growing number of applications of label-free detection techniques including protein-protein interactions, protein-ligand binding, receptor studies, antibody characterization and cell analysis boost the market’s growth rate. The growing usage of label-free detection methods in the development of personalized medicine to enable real-time analysis of patient samples, the increasing need for high-throughput screening and the rising popularity of label-free detection among academic and research settings due to their versatility, ease of use and ability to generate valuable data without the need for labeling further contribute to the market growth.

Innovations in unlabelled detection technologies and increased drug discovery programs through research partnerships between pharmaceutical companies and academic institutions drive the growth of the global label-free detection market. The growth of the pharmaceutical and biotechnology industries, the development of more sensitive non-marker technologies, and the increase of life sciences research activities in emerging markets further promote the growth rate of the label-free detection market. In addition, introducing technologically advanced products and increasing the prevalence of effective product delivery favor market growth. The label-free detection market provides many opportunities for probing interactions of the molecules without the quenching effects of labels.

Companies leading the global label-free detection market, such as AstraZeneca, GlaxoSmithKline, Sanofi, and Johnson & Johnson, have also announced plans to invest in R&D activities in emerging markets in the coming years. These increasing investments in emerging markets are escalating research and development activities, presenting growth opportunities for market players.

MARKET RESTRAINTS:

High initial setup and maintenance costs associated with label-free detection are one of the major factors hampering the market growth. The absence of standardized protocols for label-free detection techniques, limitations in sensitivity and dynamic range of label-free detection methods compared to traditional labeled techniques, sophisticated data analysis and interpretation of label-free detection techniques and lack of awareness and understanding about label-free detection methods among researchers and end-users further hinder the market growth. The competition from other established labeling methods such as fluorescence-based assays and regulatory requirements and approvals for label-free detection platforms and assays and inhibit the growth rate of the market.

Impact of COVID-19 on the global label-free detection market:

As per the research at the ETH Zurich of Switzerland, a demonstration of the LSPR (Localized Surface Plasmon Resonance) with the highest accuracy and sensitivity is used to detect RNA COVID-19. In label-free detection surface plasmon, Resonance is the market's primary technique and growth percentile indicator. For COVID-19 research, label-free products, like SPR systems and biosensors, are also used. Unfortunately, nearly 44% of clinical trials were closed due to the pandemic for a few months. However, the market players are coming up with different strategies to fight against coronavirus to help gain profits during the coming years. 

REPORT COVERAGE:

This research report on the global label-free detection market has been segmented and sub-segmented based on technology, product type, application, and region.

Label Free Detection Market - By Technology:

• Bio-layer Interferometry
• Cellular Dielectric Spectroscopy
• Optical Waveguide Grating Technology
• Surface Plasmon Resonance

Based on technology, the surface plasmon resonance segment held the major share of the global market in 2022 and the domination of the SPR segment is expected to continue in the market during the forecast period. SPR is a widely recognized and established label-free detection technology. The dominant usage of surface plasmon resonance in pharmaceutical and biotechnology industries, the increasing number of applications of SPR in drug discovery, biomolecular interactions, and quality control and the growing availability of a wide range of SPR-based instruments and consumables primarily drive the segmental growth.

Label Free Detection Market - By Product Type:

• Consumables Such as Biosensor Chips
• Microplates
• Instruments

Based on product type, the biosensor chips segment accounted for the largest share of the global market in 2022 and is expected to grow at a promising CAGR during the forecast period. The growing adoption of label-free detection technologies in drug discovery, proteomics, and molecular diagnostics, rising demand for biosensor chips for real-time monitoring of biomolecular interactions, increasing number of advancements in chip manufacturing techniques and rising focus on personalized medicine and biomarker discovery, driving the need for biosensor chips in clinical research drive the growth of the biosensor chips segment.

Label-Free Detection Market - By Application:

• Binding Kinetics
• Binding Thermodynamics
• Endogenous Receptor Detection
• Hit Confirmation
• Lead Generation

Based on application, the binding kinetics segment had the largest share of the global market in 2022. The binding kinetics segment is also predicted to witness the highest CAGR during the forecast period in the global market. The ability of binding kinetics to provide real-time, quantitative data on the rate and affinity of biomolecular interactions is one of the major factors propelling segmental growth. The growing importance of understanding the kinetic properties of drug-target interactions in drug discovery and development, the increasing number of advancements in label-free detection technologies offering improved sensitivity, resolution and data analysis capabilities and the rapid adoption of kinetic analysis in academic research, biotechnology and pharmaceutical industries further boost the growth rate of the binding kinetics segment.

Label-Free Detection Market - By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Geographically, the North American region accounted for the largest share of the global market, followed by the European countries and the Asia-pacific region in 2022. The presence of a well-established pharmaceutical and biotechnology industry, extensive research and development activities, and advanced healthcare infrastructure in North America majorly drive the growth of the North American label-free detection market. The availability of high investments in research and development of label-free detection technologies by pharmaceutical and biotech companies, the presence of key market players and academic research institutions driving innovation and adoption of label-free detection techniques, supportive government initiatives and funding for life sciences research and drug discovery and a strong focus on personalized medicine and biomarker research further fuel the growth rate of the label-free detection market in the North American region. The U.S. had the major share of the North American label-free detection market in 2022, followed by Canada.

Europe is one of the prominent regional markets for label-free detection and captured a substantial share of the global market in 2022. The European label-free detection market is predicted to grow at a notable CAGR during the forecast period. The presence of a robust life sciences sector, increasing research activities and rising emphasis on drug discovery and development primarily drive the growth of the European market. The growing number of collaborations between academic institutions, research organizations, and industry players to advance label-free detection technologies, increasing investments in healthcare infrastructure and research facilities. Favorable government policies supporting scientific research and innovation and rising demand for label-free detection in clinical diagnostics and pharmaceutical research further propel the growth of the European market. The United Kingdom held the largest share of the label-free detection market in Europe in 2022 and is expected to grow at a prominent CAGR during the forecast period due to an increasing number of pharmaceutical and biotechnology companies. France and Spain are predicted to account for a considerable share of the European market during the forecast period owing to the rise in legal take of new approaches to discovering drugs and initiative steps by the government and growing R & D activities in these countries.

The label-free detection market in the APAC region is estimated to register the highest CAGR during the forecast period. The growth of Asian economies, especially China and India, and growing biotechnology industry in this region, and increasing drug discovery investments are driving the label free detection market in Asia. Most Asian countries have not created business models but have the scientific talent to develop solid local biotech industries. In addition, many Asian economies have modified regulations, policies, and guidelines to support investment, innovation, and commercialization. As a result, research activities in the life sciences sector are increasing.

The Latin American label-free detection market is projected to hold a considerable share of the global market during the forecast period. Factors such as improving healthcare infrastructure, increasing research collaborations and rising investments in biotechnology and pharmaceutical sectors majorly propel the Latin American market growth. The rising emphasis on precision medicine and biomarker research in the region, increasing demand for label-free detection technologies in drug discovery, diagnostics, and agricultural research, growing number of initiatives from the Latin American governments to support research and development activities and rising awareness and adoption of label-free detection techniques in academic and industrial settings drive the Latin American market growth. Brazil followed by Mexico dominated the market in Latin America in 2022.

The MEA label-free detection market is projected to register a steady CAGR during the forecast period. Factors such as growing pharmaceutical and biotechnology sectors in the MEA region, increasing number of initiatives of MEA countries to promote research and development in life sciences and healthcare, rising number of collaborations between regional and international research organizations and growing focus on drug discovery, diagnostics, and personalized medicine in the region.

PROMISING COMPANIES IN THIS MARKET:

Ametek, Inc., Bio-Rad Laboratories, Inc., BiOptix, Corning, Inc., Danaher Corporation, General Electric Corporation, Pall Corporation, PerkinElmer, Attana AB, and Roche are some of the leading companies in the global label-free detection market.

RECENT HAPPENINGS IN THIS MARKET:

• In April 2019, the TA instruments launched ElectroForce 3300 series III. The flexible and powerful instrument helps achieve high efficiency in testing materials.
• In Feb 2019, Hitachi High-Technologies Corporation and Asia Clean Capital Limited became one, i.e., they collaborated in the distribution of solar power projects to develop Japanese enterprise operations in the Chinese market. 
• In June 2018, Bruker Corporation completed the acquisition of sierra sensors Gmbh to expand its product portfolio.
• In Aug 2017, Malvern Panalytical, a global leader, announced a collaboration with TetraScience partnership, a computer network providing Internet of Things (IoT) company, to deploy the IoT-enabled power to do something interconnected with the instruments. In addition, the collaboration aims to provide access to dashboards, data collection and analytics, and system scheduling and monitoring.